0001437749-26-016717
SEC filingAytu BioPharma reported fiscal 2026 Q3 net revenue of $12.4 million, down from $18.5 million prior year, with EXXUA contributing $2.4 million amid launch investments and net loss of $5.6 million.
Aytu BioPharma's fiscal 2026 third quarter results reflect a strategic pivot toward the EXXUA launch in the $22 billion MDD market, with EXXUA generating $2.4 million in net revenue despite only partial quarter sales force support following mid-December commercial availability and mid-January formal launch. Total net revenue declined 33% year-over-year to $12.4 million, primarily from reduced ADHD Portfolio sales ($9.1 million vs. $15.4 million) due to reprioritized sales force focus on EXXUA and generic entry for Adzenys XR-ODT, alongside Pediatric Portfolio weakness ($0.9 million vs. $3.1 million) from payor shifts and higher returns. Gross profit fell to $7.6 million (61% margin vs. 69% prior year), pressured by lower revenue mix, sales force transition, and a $0.7 million Adzenys-related inventory write-down. Operating expenses rose to $10.9 million from EXXUA commercialization investments, offset partially by efficiencies like reduced facilities costs, yielding Adjusted EBITDA of $(2.8) million versus $3.9 million last year. The GAAP net loss of $5.6 million included a $1.3 million derivative warrant liability loss tied to stock price appreciation, contrasting prior year's $4.0 million net income with its $2.3 million warrant gain. Balance sheet strengthened with $26.7 million cash and $35.1 million equity as of March 31, 2026, boosted by a warrant amendment eliminating $26.4 million in liabilities. CEO Josh Disbrow highlighted EXXUA's rapid script growth (1,300 prescriptions from 450 prescribers), strong titration and refill trends, and channel partner execution (3,200 units sold), positioning it as a high-growth opportunity while legacy portfolios sustain profitability. No forward guidance provided, but management emphasized disciplined execution for sustained growth.